Advertisement

Topics

PubMed Journals Articles About "Safety And Tolerability Of Pioglitazone-Azilsartan In Subjects With Type 2 Diabetes" RSS

20:00 EST 22nd January 2019 | BioPortfolio

Safety And Tolerability Of Pioglitazone-Azilsartan In Subjects With Type 2 Diabetes PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Safety And Tolerability Of Pioglitazone-Azilsartan In Subjects With Type 2 Diabetes articles that have been published worldwide.

More Information about "Safety And Tolerability Of Pioglitazone-Azilsartan In Subjects With Type 2 Diabetes" on BioPortfolio

We have published hundreds of Safety And Tolerability Of Pioglitazone-Azilsartan In Subjects With Type 2 Diabetes news stories on BioPortfolio along with dozens of Safety And Tolerability Of Pioglitazone-Azilsartan In Subjects With Type 2 Diabetes Clinical Trials and PubMed Articles about Safety And Tolerability Of Pioglitazone-Azilsartan In Subjects With Type 2 Diabetes for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Safety And Tolerability Of Pioglitazone-Azilsartan In Subjects With Type 2 Diabetes Companies in our database. You can also find out about relevant Safety And Tolerability Of Pioglitazone-Azilsartan In Subjects With Type 2 Diabetes Drugs and Medications on this site too.

Showing "Safety Tolerability Pioglitazone Azilsartan Subjects With Type Diabetes" PubMed Articles 1–25 of 22,000+

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial.

Choices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects. However, weight gain and fluid retention are major clinical problems for pioglitazone among patients with CKD. We conducted this study to compare the efficacy and side effects of low dose pioglitazone with standard dose pioglitazone among patients with type 2 diabete...


Safety and Tolerability of Combinations of Empagliflozin and Linagliptin in Patients with Type 2 Diabetes: Pooled Data from Two Randomized Controlled Trials.

Two 52-week Phase III studies evaluated the efficacy and safety of once-daily combinations of empagliflozin/linagliptin as monotherapy or add-on to metformin in patients with type 2 diabetes (T2DM). The aim of this analysis was to further assess the safety and tolerability of empagliflozin/linagliptin compared with their individual components in patients with T2DM, using pooled data from these trials.

Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study.

To assess quality of life, glycemic control, and safety/tolerability associated with liraglutide versus insulin initiation in patients with type 2 diabetes in Germany.


Detecting Pioglitazone Use and Risk of Cardiovascular Events Using Electronic Health Record Data in a Large Cohort of Chinese Patients with Type 2 Diabetes.

Pioglitazone may have a protective effect on cardiovascular disease risk among type 2 diabetes patients but evidence from China is lacking. Our study aimed to investigate the association using massive electronic health records data from a Chinese cohort of type 2 diabetes patients.

Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects.

Tylerdipine hydrochloride (KBP-5660) is a novel L/T-type dual calcium channel blocker developed for the treatment of hypertension. We aimed to study the pharmacokinetics, safety and tolerability of tylerdipine in healthy Chinese subjects.

Pioglitazone Induces Cardiomyocyte Apoptosis and Inhibits Cardiomyocyte Hypertrophy Via VEGFR-2 Signaling Pathway.

Pioglitazone has been widely used as an insulin-sensitizing agent for improving glycemic control in patients with type 2 diabetes mellitus. However, cardiovascular risk and protective effects of pioglitazone remain controversial.

Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials.

This study was designed to evaluate the efficiency and tolerability of empagliflozin (EMPA) as monotherapy or add-on to existing therapy in patients with type 2 diabetes mellitus (T2DM).

Periodontitis links to exacerbation of myocardial dysfunction in subjects with type 2 diabetes.

Subjects with diabetes and periodontitis are at high risk of cardiovascular events, while the subclinical alterations of cardiac function in this cohort remain unclear. This cross-sectional study investigated the association of periodontitis with left ventricle (LV) structural and functional abnormalities in subjects with type 2 diabetes mellitus (T2DM).

Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.

Ipragliflozin is a new antidiabetic agent that works through enhancing renal glucose excretion. We aim to synthesize evidence from published randomized controlled trials (RCTs) on the safety and efficacy of ipragliflozin in the management of type 2 diabetes mellitus (T2DM).

A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.

We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension.

Bladder Cancer In Patients With Type 2 Diabetes Treated With Pioglitazone, A Comparative Study.

This study was conducted to determine the frequency of bladder cancer in diabetic mellitus type II patients treated with Pioglitazone as compared with diabetic mellitus type II patients treated with other oral therapy or insulin therapy.

Plasma Irisin Levels in Subjects with Type 1 Diabetes: Comparison with Healthy Controls.

Irisin is a myokine that increases energy expenditure. In this cross-sectional study, we examined for differences in plasma irisin concentrations between subjects with type 1 diabetes mellitus and healthy individuals and searched for associations between plasma irisin levels and clinical and biochemical characteristics as well as self-reported physical activity. A total of 79 subjects with type 1 diabetes [age 38.2±12.5 years, men/women (n): 27/52], were consecutively recruited. Moreover, 53 healthy contro...

A long-acting pegylated recombinant human growth hormone (Jintrolong ) in healthy adult subjects: Two single-dose trials evaluating safety, tolerability and pharmacokinetics.

Jintrolong is a pegylated recombinant human growth hormone (rhGH) (PEG-rhGH) developed for weekly subcutaneous (sc) injection. The current human tolerability trial and pharmacokinetics (PK) trial evaluated the safety, tolerability and PK of single-dose Jintrolong injection in healthy adult subjects.

Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials.

To assess the efficacy and safety profile of the dipeptidyl-peptidase-4 inhibitor sitagliptin in a population of self-identified Hispanic/Latino patients with type 2 diabetes.

Long-Term Compliance, Safety, and Tolerability of Sodium Oxybate Treatment in Patients with Narcolepsy Type 1: A Post-Authorization, Non-Interventional Surveillance Study.

To evaluate adherence to sodium oxybate prescribing information for indication and dosage, patients' compliance with instructions for use, safety/tolerability in routine clinical practice, and abuse potential.

Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety.

Real-world evidence on effectiveness and safety of insulin degludec (IDeg) in patients with diabetes is a priority. The aim of the study was to evaluate patterns of use and the long-term effectiveness and safety of IDeg in routine clinical practice.

Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.

Novel therapies to treat chronic obstructive pulmonary disease are highly desirable. The safety, tolerability, and pharmacokinetic (PK) parameters of nemiralisib, a phosphoinositide 3-kinase δ inhibitor, administered via the Ellipta dry powder inhaler (GlaxoSmithKline, Research Triangle Park, North Carolina) was evaluated, including an assessment of oral bioavailability.

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up-titration in treatment of patients with type 2 diabetes: the CompoSIT-M Study.

To characterize the glycemic efficacy and safety of initiation of the DPP-4 inhibitor sitagliptin during metformin dose escalation in participants with type 2 diabetes (T2D) not at HbA1c goal on a sub-maximal dose of metformin.

News in diabetology 2018.

Diabetes is a rapidly evolving discipline, numerous new molecules and technologies are available. This allows for a better follow up of our patients with type 1 and type 2 diabetes. Moreover, every new molecule devoted to treat type 2 diabetes must undergo a cardiovascular safety study. In recent years, some of these studies proved to be beneficial for some of our patients. Nevertheless, this pharmacological plethora is paradoxically associated with clinical inertia as general practitioners may be in troubl...

Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects.

Fasting hyperglucagonemia can be detrimental to glucose metabolism in patients with type 2 diabetes (T2D) and may contribute to metabolic disturbances in obese and/or prediabetic subjects. However, the mechanisms underlying fasting hyperglucagonemia remain elusive.

Blood Pressure and Development of Cardiovascular Disease in Koreans With Type 2 Diabetes Mellitus.

The objective of this study was to investigate the optimal blood pressure (BP) target to prevent development of cardiovascular diseases (CVDs) in Korean subjects with type 2 diabetes mellitus. Using the Korean National Health Insurance Service database, 2 262 725 subjects with type 2 diabetes mellitus who underwent regular health checks between 2009 and 2012 were included. Subjects with previous CVDs were excluded. Participants were grouped by 10-mm Hg intervals of observed systolic BP (SBP) by 5-mm...

Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

To evaluate the safety of in-home use of the MiniMed™ 670G system with SmartGuard™ technology in children with type 1 diabetes (T1D).

Association of Gestational Diabetes and Type 2 Diabetes Exposure In Utero With the Development of Type 2 Diabetes in First Nations and Non-First Nations Offspring.

Type 2 diabetes is increasing worldwide, disproportionately affecting First Nations (FN) people. Identifying early-life determinants of type 2 diabetes is important to address the intergenerational burden of illness.

The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.

The aim is to evaluate the efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP4-I: sitagliptin, saxagliptin, linagliptin, vildagliptin and alogliptin) in patients with type 2 diabetes.

Skin autofluorescence is associated with high-sensitive cardiac troponin T, a circulating cardiac biomarker, in Japanese patients with diabetes: A cross-sectional study.

The study aims to evaluate the relationship between skin autofluorescence, a marker of advanced glycated end-products accumulation in tissue, and high-sensitive cardiac troponin T, a cardiovascular biomarker, in Japanese subjects with diabetes. A total of 145 subjects with diabetes and 32 nondiabetic subjects as control attending the outpatient clinic were examined. Skin autofluorescence was measured using the AGE Reader™. Univariate and multivariate regression analyses were used to identify the factors a...


Advertisement
Quick Search
Advertisement
Advertisement